title: Dendritic cells and innate defense against tumor cells.
abstract: Tumor growth results from a delicate balance between intrinsic dysregulation of oncogenes, tumor suppressor and stability genes counteracted by extrinsic defenses composed of immune cells shaping tumor immunogenicity. Although immune subversion might be the ultimate outcome of this process, a complex network of cellular interactions take place eventually leading to tumor specific cognate immune responses. The links between innate and cognate antitumor immunity eliciting protective T cell responses are instigated by cytokines, chemokines and damage associated molecular patterns. The intricate differentiation pathway whereby dendritic cells could undergo an efficient maturation program in the tumor microenvironment appears crucial. We will discuss the role of innate effectors and cancer therapies in the process of defense against tumor cells.
authors.affiliation: Institut Gustave Roussy, Villejuif, France. ullrich@igr.fr
authors.forename: Evelyn
authors.initials: E
authors.lastname: Ullrich
authors.forename: Cédric
authors.initials: C
authors.lastname: Ménard
authors.forename: Caroline
authors.initials: C
authors.lastname: Flament
authors.forename: Magali
authors.initials: M
authors.lastname: Terme
authors.forename: Grégoire
authors.initials: G
authors.lastname: Mignot
authors.forename: Mathieu
authors.initials: M
authors.lastname: Bonmort
authors.forename: Jöel
authors.initials: J
authors.lastname: Plumas
authors.forename: Laurence
authors.initials: L
authors.lastname: Chaperot
authors.forename: Nathalie
authors.initials: N
authors.lastname: Chaput
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000378:metabolism; D019496:Cancer Vaccines / Q000627:therapeutic use; D018899:CpG Islands; D016207:Cytokines / Q000502:physiology; D003713:Dendritic Cells / Q000276:immunology*; D053222:Fas Ligand Protein / Q000502:physiology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D024243:HMGB1 Protein / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D007113:Immunity, Innate / Q000276:immunology*; D007370:Interferon Type I / Q000502:physiology; D007371:Interferon-gamma / Q000502:physiology; D007372:Interferons / Q000096:biosynthesis; D019409:Interleukin-15 / Q000502:physiology; D007694:Killer Cells, Natural / Q000276:immunology; D009369:Neoplasms / Q000276:immunology*; D009838:Oligodeoxyribonucleotides / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D020239:Receptor Cross-Talk / Q000502:physiology; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014527:Uric Acid / Q000378:metabolism
chemical_list: D001549:Benzamides; D014408:Biomarkers, Tumor; C408982:CPG-oligonucleotide; D019496:Cancer Vaccines; D016207:Cytokines; D053222:Fas Ligand Protein; D024243:HMGB1 Protein; D007370:Interferon Type I; D019409:Interleukin-15; D009838:Oligodeoxyribonucleotides; D010879:Piperazines; D011743:Pyrimidines; D014527:Uric Acid; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D007372:Interferons